Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The trial is a phase II trial in adrenocortical carcinoma (ACC), a rare malignancy with poor
prognosis. It will provide results leading to the establishment of the effect of the included
drugs. The regimen consists of cisplatin plus taxotere. Over a period of 1-2 years this
national trial will include 19-36 patients with advanced ACC from different centres in
Denmark. Patients not responding to the first line treatment will be switched to the
alternative regimen. The primary objective of this trial is to investigate response rate.
Secondary endpoints are survival, time to progression, best overall response rate and
duration of response.